Goodwin Guides Prime Medicine on Pricing of $125 Million Public Offering

The Life Sciences team advised Prime Medicine, Inc. (“Prime”) on its underwritten public offering of 35,714,286 shares of common stock at a public offering price of $3.50 per share. The aggregate gross proceeds to Prime from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and other offering expenses. Prime has also granted the underwriters a 30-day option to purchase up to an additional 5,357,142 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions.

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. Prime is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.

The Goodwin team was led by Marishka DeToy, Karin Yoo, Haylee Brown, Rachel Staats, and Kingsley Taft.

For more information on the deal, please read the press release.